Don't miss this exceptional opportunity to be selected as a Investment Fellow or Investor-in-Residence of at Maroon Venture Fund or Maroon Research Institute.
ROLE DESCRIPTION includes support/collaboration in the following areas:
• Venture Building & Translational Medicine in the areas of Neurological & Brain Health, Autoimmune Disorders (incl. Inflammation), Climate-Health Impact, Children & Womens Health, or Sports/High Performance Groups
• R&D Design and Project Management
• Technology Transfer and/or Commercialisation
• Due Diligence and ** Preparation & Presentation ** of Investment Memos to Investment Committee to support early-stage venture capital or debt investments
• Strategic Partnership Management
REQUIRED QUALIFICATIONS
Applicants should be able to evidence:
• 5 -10 years of demonstrated successful innovation commercialisation, venture due diligence, or investment expertise/track record
• 5-10 years of Investment Track Record in Investment Banking, Venture Capital, Family Offices, Venture Debt, Strategic Investors or as an Institutional Investor
• Exceptional analytical, written, and verbal communication skills
• Strong alignment with Institute areas of expertise in Precision Medicine & Preventative Health for chronic Population Health conditions, or Climate-Health Impact
APPLICATION DEADLINE: 15 March 2026
WEBSITE: www.marooninvestglobal.com
WEBSITE: www.maroon-institute.com
ELIGIBLE CITIES / COUNTRIES
• USA incl. Arizona, California, Texas, New York, Massachusetts, Maryland, Virgina
• United Kingdom
• Singapore, South Korea, Hong Kong, Malaysia
• UAE, Saudi Arabia
MAROON RESEARCH INSTITUTE
Maroon Research Institute (MRI) is a 501c3 sponsored U.S. based non-profit with global operations in 17 countries including major Hubs in San Francisco for the USA; Singapore for Asia; and Abu Dhabi for EMEA. MRI is committed to advancing Healthy Aging, Healthspan & Longevity Science by tackling head on critical areas that have been under-innovated and under-funded ~ and accelerating the full innovation-commercialization lifecycle to advance proactive, personalized, Precision Medicine & Preventative Healthcare for the early diagnosis, detection, and reduction in chronic Population Health conditions, and reduction in negative direct Climate Impact on Health.
LAUNCHING MAR 2026 - MRI Global Venture Studio for HealthSpan & Healthy Longevity Science
MRI VENTURE STUDIO ADVANCES 4 PILLARS in Longevity Science
Science-driven protocols, diagnostics and therapies across Precision & Integrated Medicine for Preventative Health outcomes for chronic Population Health conditions ~ and excludes Lifestyle Only solutions, late stage Pharma
INCLUDES:
Neurological Disorders and Brain Health
Autoimmune Disorders include Diabetes & Inflammation
Blood & Cardiovascular Health
Direct Climate Impact on Health incl. Exposomes, Food & Environmental allergies, Built Environment (air & water quality, respiratory health), and Blue Economy / Marine Biotech for Human Health
DEMOGRAPHICS:
Children & Womens Health (excl. sexual & reproductive health)
Mens Health
Sports Medicine & High Performance Groups
VENTURE STUDIO BENEFITS
Successful fellows and EIRs will benefit from a value creation partnership with Institute for measurable innovation and commercial scaling delivery at scale:
1 - Potential for Funding at Pre-Seed to Series B including venture capital, venture debt, revenue sharing, or recoverable grants
2 - Research & Innovation support incl. research studies, laboratory facilities, clinical trials, and participation in Institute’s Global R&D Hub Exchange Program
3 – Commercialization roadmap execution incl. pilots and partnerships
4 - AI Integration and scaling at MRI Hubs
Fellows benefit from (subject to meeting application criteria) for complimentary acceptance to MRI’s Longevity Science Venture Studio with access to funding (venture capital, debt, philanthropic grants) working with an expert research & commercialization team, Artificial Intelligence operating partners, and some of the world's leading research institutions and corporate partners.